1352893-24-3

Basic information

• Product Name: 6-chlorofuro[3,4-c]pyridin-3(1H)-one
• Synonyms: 6-chlorofuro[3,4-c]pyridin-3(1H)-one;6-chloro-1H,3H-furo[3,4-c]pyridin-3-one
• CAS NO: 1352893-24-3
• Molecular Formula: C7H4ClNO2
• Molecular Weight: 169.56516
• Mol File: 1352893-24-3.mol

Chemical Properties

• Boiling Point: 388.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.524±0.06 g/cm3(Predicted)
• PKA: -1.27±0.20(Predicted)
• CAS DataBase Reference: 6-chlorofuro[3,4-c]pyridin-3(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chlorofuro[3,4-c]pyridin-3(1H)-one(1352893-24-3)
• EPA Substance Registry System: 6-chlorofuro[3,4-c]pyridin-3(1H)-one(1352893-24-3)

Safety Data

• Hazardous Substances Data: 1352893-24-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
6-Chlorofuro[3,4-c]pyridin-3(1H)-one serves as a valuable building block in the synthesis of a variety of organic molecules. Its distinctive ring structure and functional groups make it a versatile component for creating complex organic compounds.
Used in Pharmaceutical Research:
In the realm of pharmaceuticals, 6-chlorofuro[3,4-c]pyridin-3(1H)-one is considered a potential drug candidate. Its unique chemical properties and reactivity may contribute to the development of new therapeutic agents, warranting further exploration and study.
Used in Medicinal Chemistry:
6-chlorofuro[3,4-c]pyridin-3(1H)-one's behavior in chemical reactions and its properties make it an intriguing subject for research within medicinal chemistry. Understanding its interactions and potential modifications can lead to advancements in drug discovery and design.
Used in Drug Discovery:
6-Chlorofuro[3,4-c]pyridin-3(1H)-one's potential as a precursor in drug discovery highlights its importance in the development of novel pharmaceuticals. Its unique structure may offer new avenues for treating various diseases and conditions, making it a promising target for research and development in the pharmaceutical industry.

Upstream product

• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 905273-87-2 6-chloro-N,N-bis(propan-2-yl)pyridine-3-carboxamide 
• 905273-88-3 6-chloro-4-formyl-N,N-bis(propan-2-yl)pyridine-3-carboxamide 
• 1425335-86-9 6-chloro-4-(hydroxymethyl)-N,N-bis(propan-2-yl)pyridine-3-carboxamide 

Downstream Products

• 1450723-16-6 6-amino-N-[[4-(benzenesulfonyl)phenyl]methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide 
• 1450723-54-2 6-chloro-2-[(2,4-dimethoxyphenyl)methyl]-1H,2H,3H-pyrrolo[3.4-c]pyridine 
• 1450723-55-3 N,2-bis[(2.4-dimethoxyphenyl)methyl]-1H,2H,3H-pyrrolo[3,4-c]pyridin-6-amine 
• 1453272-30-4 2-chloro-4,5-bis(chloromethyl)pyridine hydrochloride 

Relevant articles and documents

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors

NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moieties also led to consistent and potent inhibition of CYP2C9. In an attempt to reduce CYP2C9 inhibition, a parallel synthesis approach was used to identify central benzyl group replacements with increased Fsp3. A spirocyclic central motif was thus discovered that was combined with left-hand pyridines (or pyridine-like systems) to provide cellularly potent NAMPT inhibitors with minimal CYP2C9 inhibition. Further optimization of potency and ADME properties led to the discovery of compound 68, a highly potent NAMPT inhibitor with outstanding efficacy in a mouse tumor xenograft model and lacking measurable CYP2C9 inhibition at the concentrations tested.

Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors containing 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas were identified using structure-based design techniques. The new compounds displayed improved aqueous solubilities, determined using a high-throughput solubility assessment, relative to previously disclosed urea and amide-containing NAMPT inhibitors. An optimized 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived compound exhibited potent anti-NAMPT activity (18; BC NAMPT IC50 = 11 nM; PC-3 antiproliferative IC50 = 36 nM), satisfactory mouse PK properties, and was efficacious in a PC-3 mouse xenograft model. The crystal structure of another optimized compound (29; NAMPT IC50 = 10 nM; A2780 antiproliferative IC50 = 7 nM) in complex with the NAMPT protein was also determined.

AMIDO-BENZYL SULFONE AND SULFONAMIDE DERIVATIVES

Disclosed are certain amido-benzyl sulfone and sulfonamide compounds, pharmaceutical compositions comprising such compounds, land methods of treatment using such compounds.